NYSE:TARO - Taro Pharmaceutical Industries Stock Price, Forecast & News

Taro Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TARO."

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced its quarterly earnings results on Monday, November, 4th. The company reported $1.46 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $1.72 by $0.26. The firm had revenue of $160.85 million for the quarter, compared to the consensus estimate of $168.60 million. Taro Pharmaceutical Industries had a net margin of 40.43% and a return on equity of 14.13%. View Taro Pharmaceutical Industries' Earnings History.

Taro Pharmaceutical Industries is scheduled to release their next quarterly earnings announcement on Wednesday, February 5th 2020. View Earnings Estimates for Taro Pharmaceutical Industries.

1 brokers have issued 1-year target prices for Taro Pharmaceutical Industries' shares. Their forecasts range from $110.00 to $110.00. On average, they anticipate Taro Pharmaceutical Industries' share price to reach $110.00 in the next year. This suggests a possible upside of 18.5% from the stock's current price. View Analyst Price Targets for Taro Pharmaceutical Industries.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Taro Pharmaceutical Industries in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Taro Pharmaceutical Industries.

Media headlines about TARO stock have been trending negative recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Taro Pharmaceutical Industries earned a coverage optimism score of -2.8 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Taro Pharmaceutical Industries.

Taro Pharmaceutical Industries saw a increase in short interest in November. As of November 29th, there was short interest totalling 297,400 shares, an increase of 6.5% from the November 14th total of 279,200 shares. Based on an average trading volume of 79,500 shares, the days-to-cover ratio is presently 3.7 days. Approximately 3.3% of the shares of the stock are short sold. View Taro Pharmaceutical Industries' Current Options Chain.

Some companies that are related to Taro Pharmaceutical Industries include Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Bausch Health Companies (BHC), Teva Pharmaceutical Industries (TEVA), Elanco Animal Health (ELAN), Mylan (MYL), Ono Pharmaceutical (OPHLF), Ionis Pharmaceuticals (IONS), Amarin (AMRN), Beigene (BGNE), Jazz Pharmaceuticals (JAZZ), Catalent (CTLT), Sarepta Therapeutics (SRPT) and Perrigo (PRGO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Taro Pharmaceutical Industries investors own include Gilead Sciences (GILD), Broadcom (AVGO), Bausch Health Companies (BHC), Teva Pharmaceutical Industries (TEVA), Skyworks Solutions (SWKS), Supernus Pharmaceuticals (SUPN), Celgene (CELG), Jazz Pharmaceuticals (JAZZ), Neurocrine Biosciences (nbix) and Southwest Airlines (LUV).

Taro Pharmaceutical Industries' stock is owned by a variety of of institutional and retail investors. Top institutional investors include CLARET ASSET MANAGEMENT Corp (0.22%), Millennium Management LLC (0.21%), California Public Employees Retirement System (0.11%), Systematic Financial Management LP (0.02%) and Squarepoint Ops LLC (0.01%).

TARO stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, CLARET ASSET MANAGEMENT Corp and Systematic Financial Management LP.

TARO stock was acquired by a variety of institutional investors in the last quarter, including California Public Employees Retirement System and Squarepoint Ops LLC.

Shares of TARO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TARO stock can currently be purchased for approximately $92.83.

Taro Pharmaceutical Industries has a market capitalization of $3.58 billion and generates $669.89 million in revenue each year. The company earns $281.78 million in net income (profit) each year or $7.23 on an earnings per share basis. Taro Pharmaceutical Industries employs 1,464 workers across the globe.View Additional Information About Taro Pharmaceutical Industries.

The official website for Taro Pharmaceutical Industries is http://www.taro.com/.

Taro Pharmaceutical Industries' mailing address is 14 HAKITOR ST PO BOX 10347, HAIFA BAY L3, 10532. The company can be reached via phone at 972-4847-5700 or via email at [email protected]